NARA Discovery
Article Details
← Back to Search Results
Journal Article

Inactivation of ornithine aminotransferase by (1R,4S)-4-Amino-3-(trifluoromethyl)cyclopent-2-ene-1-carboxylic acid via a stable quinonoid intermediate

Koon Mook Kang; Abigail L. Vargas; Wei Zhu; Inna Sokolenko; Dali Liu; Richard B. Silverman
Medicinal Chemistry Research · Vol. 35, Issue 4 · pp. 792-803 · 2026

Abstract

Ornithine aminotransferase (OAT), a pyridoxal 5’-phosphate (PLP)-dependent enzyme, is a key contributor to glutamine supply in cancer cells, suggesting its therapeutic potential for hepatocellular carcinoma (HCC), the most common form of liver cancer. To identify an initial set of OAT inactivators, we have tested inactivators of γ-aminobutyric acid aminotransferase (GABA-AT), a homologous PLP-dependent enzyme, with human OAT ( h OAT) and identified several co-inactivators. Among the active molecules, (1 R ,4 S )-4-amino-3-(trifluoromethyl)cyclopent-2-ene-1-carboxylic acid ( 2 ) has not been thoroughly investigated for its time-dependent kinetics and mechanistic pathways with OAT. In this study, we evaluated the time-dependent inactivation of h OAT by 2 and investigated the underlying mechanism, primarily based on X-ray crystallography. The results demonstrated that 2 acts as a time-dependent OAT inactivator with an inactivation efficiency ( k inact / K I = 5.1 min −1 mM −1 ) approximately 30-fold higher than that for GABA-AT ( k inact / K I = 0.17 min −1 mM −1 ) and, notably, revealed an inactivation pathway that proceeds via a stable quinonoid intermediate, as evidenced by the UV-Vis spectroscopy.

Bibliographic Information

JournalMedicinal Chemistry Research
PublisherSpringer
Publication Date2026-04-01
Publication Year2026
Volume35
Issue4
Pages792-803
Document TypeJournal Article
Print ISSN1054-2523
eISSN1554-8120
DOI10.1007/s00044-026-03538-1

Access Information

NARA Access Coverage2004-01-01~Current
Journal Homepagehttps://www.springer.com/journal/44
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.